Literature DB >> 30041832

Universal varicella vaccination increased the incidence of herpes zoster in the child-rearing generation as its short-term effect.

Nozomu Toyama1, Kimiyasu Shiraki2.   

Abstract

BACKGROUND: Effects of universal varicella vaccination on the herpes zoster (HZ) incidence have not been elucidated. Universal varicella vaccination was introduced in Japan in October 2014.
OBJECTIVE: We investigated the effects of universal varicella vaccination on HZ epidemiology.
METHODS: Patients with HZ have been monitored by the Miyazaki Dermatologist Society since 1997, and the effects of universal vaccination on the HZ incidences have been analyzed to determine which generation is most affected.
RESULTS: The number of HZ patients increased 1.54 times, and the gradual increase in the HZ incidence was observed in not only patients >60 years, but also other generations during the period from 1997 to 2017. The number of varicella patients was gradually reduced from 2010 to 2017 before introduction of universal varicella vaccination, and the HZ incidence in yearly change significantly increased from 2014 to 2016 in the total population associated with the significant decrease in varicella incidence. The HZ incidence significantly increased for individuals aged 20 to 49 years from 2014 to 2015 and most for individuals age 20-29 years (odds ratio [OR], 1.270; 95% confidence interval [CI], 1.071-1.505, P<0.001). We identified the child-rearing generation of age 20 to 49 years (OR, 1.270; 95% CI, 1.071-1.505, P<0.001) as the generation most influenced by universal varicella vaccination, when the HZ incidence increased gradually by approximately 2% per year.
CONCLUSIONS: Universal vaccination increased the HZ incidence in the child-rearing generation among the generations, possibly by reduced chance of boosting their immunity by exposure to varicella.
Copyright © 2018 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Child-rearing generation; Epidemiology; Herpes zoster; Immunity; Universal vaccination; Varicella

Mesh:

Substances:

Year:  2018        PMID: 30041832     DOI: 10.1016/j.jdermsci.2018.07.003

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  7 in total

1.  Incidence of varicella and herpes zoster after inclusion of varicella vaccine in national immunization schedule in Turkey: time trend study.

Authors:  Ahmet Soysal; Erdem Gönüllü; İsmail Yıldız; Metin Karaböcüoğlu
Journal:  Hum Vaccin Immunother       Date:  2020-07-23       Impact factor: 3.452

2.  Routine varicella vaccination program and hospitalization for herpes zoster in Japan.

Authors:  Yasutaka Kuniyoshi; Haruka Tokutake; Natsuki Takahashi; Azusa Kamura; Sumie Yasuda; Makoto Tashiro
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 4.526

3.  A systematic literature review of herpes zoster incidence worldwide.

Authors:  Désirée van Oorschot; Hilde Vroling; Eveline Bunge; John Diaz-Decaro; Desmond Curran; Barbara Yawn
Journal:  Hum Vaccin Immunother       Date:  2021-03-02       Impact factor: 3.452

Review 4.  Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster.

Authors:  Kimiyasu Shiraki; Shinichiro Yasumoto; Nozomu Toyama; Hiroaki Fukuda
Journal:  Viruses       Date:  2021-08-05       Impact factor: 5.048

5.  Varicella zoster virus vaccines: an update.

Authors:  Giovanni Gabutti; Niccolò Bolognesi; Federica Sandri; Caterina Florescu; Armando Stefanati
Journal:  Immunotargets Ther       Date:  2019-08-06

6.  Reconstructing the transmission dynamics of varicella in Japan: an elevation of age at infection.

Authors:  Ayako Suzuki; Hiroshi Nishiura
Journal:  PeerJ       Date:  2022-01-19       Impact factor: 2.984

Review 7.  Effect of Routine Varicella Immunization on the Epidemiology and Immunogenicity of Varicella and Shingles.

Authors:  Naruhito Otani; Masayuki Shima; Takuma Yamamoto; Toshiomi Okuno
Journal:  Viruses       Date:  2022-03-12       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.